(Photo: iStock)
The Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Dexamethasone 0.1% (Maxidex) 5ml eye drops.
Dexamethasone 0.1% (Maxidex®) eye drops, indicated for the treatment of non-infectious inflammatory conditions affecting the anterior segment of the eye, will be in short supply until early August 2021 due to a manufacturing issue.
The 10ml pack size has recently been discontinued and is no longer available. In order to conserve remaining stock, Novartis Pharmaceuticals UK LTD are supplying directly to customers on an allocation basis; however this supply will not meet national demand.
As a result, all patients who are on long term Maxidex® 0.1% will need to be reviewed and switched onto either a dexamethasone 0.1% preservative free preparation or an alternative product until the resupply date.

Organisations who already hold accounts with Novartis can place orders directly via Electronic Data Interchange (EDI), email or telephone.

If you want to share your stories and/or experiences with us, please send an email to [email protected]